Rich Yu talks about how incubator saving water during CA drought

One Bench at a Time

Rich Yu talks about how incubator saving water during CA drought

Richard Yu, Ph.D., scientific and operations director for the QB3@953 incubator in San Francisco, told GEN his facility is also heeding the need for water conservation.

“I flagged a person for using cold running water to cool an eletrophoresis gel and begged them to use a recirculating water chiller, and then hooked them up to someone using that,” Dr. Yu said. “Our autoclave and R.O. [reverse osmosis] water purifier use a lot of water for cooling and purification, respectively. We’re looking into solutions to reduce generation of, or reuse, “waste” water (in these examples, just warmed water or higher salt water). A large cistern to capture warmed water from the autoclave, and then letting it cool and recirculating it for later recooling, or some active electric chiller, are options we’re looking at but haven’t settled on anything yet.

Other biopharma users can be expected to embrace water conservation, as businesses in general have done in recent years, one close observer of California’s water challenges told GEN.

“We’ve seen this in the past, where our businesses immediately are able to increase production and reduce water usage by things like water reuse and recycling on site,” said Conner Everts, co-facilitator for the Environmental Water Caucus at Los Angeles Waterkeeper, a nonprofit whose advocacy centers on protecting and restoring Santa Monica Bay, San Pedro Bay, and adjacent waters.

From “California Drought Leaves Biopharma Thirsty for Answers,” a May 7 story in Genetic Engineering & Biotechnology News by reporter Alex Philippidis

Read the original article

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter